The Clarity study will assess the clinical and economic value of Aclarion’s Nociscan in spine surgery. The medtech company reached full funding for the trial with nearly $20 million, according to a Feb. 4 news release.
Nicholas Theodore, MD, of Baltimore-based Johns Hopkins, is leading the trial. Patients who are scheduled to have surgery for 1- or 2- level discogenic low back pain will be included, and they’ll all have a Nociscan before their procedures.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
